Depression drug developer NRX Pharmaceuticals' Q3 loss narrows
Overview
US biopharma firm reported Q3 net patient service revenue rose yr/yr on HOPE clinics growth
Company posted Q3 net loss of $2.2 mln, or $0.05 per share, narrowing from prior year
FDA approved first drug, preservative-free ketamine; commercial launch underway with 17-person sales force
Outlook
Company expects initial US market for preservative-free ketamine at $400 mln, growing 15% annually
Company plans to add more sterile injectable products in 2027, aiming to double market opportunity
Result Drivers
HOPE CLINICS GROWTH - Company attributed higher Q3 net patient service revenue to growth at HOPE Therapeutics clinics
COMMERCIAL LAUNCH PREPARATION - Higher selling, general and administrative expenses driven by preparations for preservative-free ketamine launch
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Loss Per Share | $0.05 |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for NRX Pharmaceuticals Inc is $47.00, about 2,086% above its November 16 closing price of $2.15
Reuters Recommended Reads
Nov 16 - CNS Pharmaceuticals Q3 net loss narrows as R&D costs fall
Nov 16 - Cue Biopharma Q3 net loss widens on higher R&D costs
Nov 16 - ORIC Pharmaceuticals Q3 net loss widens as R&D expenses rise
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)